SlideAbout Us Our mission is to accelerate the discovery of safe and effective therapeutic strategies targeting rare and difficult to treat cancers. BioXplor was established in 2017 and consists of an experienced, multidisciplinary team of experts in computational sciences, biomedical sciences, drug discovery and clinical development. The company is backed by leading startup accelerators including SkyDeck (UC Berkeley), Merck, Creative Destruction Labs (University of Oxford), European Institute of Technology and Innovation (EIT Health) and European Innovation Council (EIC / Horizon 2020). BioXplor's investors include UC Berkeley's SkyDeck Fund, Enterprise Ireland and IronFire Ventures. Our clients and partners include top tier pharmaceutical companies like Novartis, Amgen, Bayer and Merck.


SlideMark Rogers, MSc Co-Founder & CEO Co-Founder & COO Co-Founder & CTO Anna O'Leary, BA Pavel Kartasev, MEng, MSc Head of Machine Learning John Conway, MSc Advisor Advisor Advisor David Kwon, MD, PhD, MBA Prof. Jody J. Haigh, PhD Bill Allison Clinical Development Director Pharmacology and Therapeutics CTO at UC Berkeley